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Abstract
Purpose: To develop a simple model of therapeutic and stray absorbed dose for a variety of
treatment machines and techniques without relying on proprietary machine-speciﬁc parameters.
Methods: Dosimetry measurements conducted in this study and from the literature were used to
develop an analytical model of absorbed dose from a variety of treatment machines and techniques
in the 6 MV to 25 MV interval. A modiﬁed one-dimensional gamma-index analysis was performed
to evaluate dosimetric accuracy of the model on an independent dataset consisting of measured
dose proﬁles from seven treatment units spanning four manufacturers.
Results: The average diﬀerence between the calculated and measured absorbed dose values was
9.9% for those datasets on which the model was trained. Additionally, These results indicate that
the model can provide accurate calculations of both therapeutic and stray radiation dose from a
wide variety of radiotherapy units and techniques.
Conclusions: We have developed a simple analytical model of absorbed dose from external beam
radiotherapy treatments in the 6 MV to 25 MV beam energy range. The model has been tested
on measured data from multiple treatment machines and techniques and is broadly applicable to
contemporary external beam radiation therapy.
Keywords: out-of-field dose, absorbed dose, analytical model, external beam radiotherapy
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I. INTRODUCTION
The goal of modern external beam radiotherapy is to deliver a highly targeted radia-
tion dose to a diseased anatomic location or region while sparing the the rest of the body.
However, in practice, the whole body is unavoidably exposed to unwanted stray radiation.
Healthy tissue in the margin of the treatment ﬁeld will receive absorbed doses on the order
of the prescribed dose. Tissues outside the treatment ﬁeld receive stray dose from scattered
and leakage radiation that is one to four orders of magnitude smaller [1]. Historically, clinical
practices focused almost exclusively on in-ﬁeld exposures because of their prime importance
to curing primary cancers. In recent years, 5-year survival rates have supassed 69% for all
cancers [2] and 80% for childhood cancers [3], but a myriad of radiation epidemiology studies
have revealed the high prevalence of radiation-induced late eﬀects including cardiac toxicity
and radiogenic second cancers[4, 5]. Most radiogenic second cancers occur outside the ther-
apeutic radiation ﬁeld [6–10]. For these reasons, there is increasing interest in knowing the
small stray radiation exposures to the whole body.
Many researchers have reported algorithms to model absorbed dose from external beam
photon radiation therapy [11–14]. In general, these algorithms accurately predict exposures
inside and immediately outside the high-dose treatment ﬁeld. However, none of these al-
gorithms have fully addressed the stray dose far from the treatment ﬁeld. Stovall et al.
described three main sources of stray radiation from external beam radiation therapy de-
livered with electron linear accelerators [15]. Radiation scattered from the treatment head,
known as head scatter, is primarily important within about 10 cm from the ﬁeld edge. Pa-
tient scatter is an important source up to around 30 cm from the ﬁeld edge. Finally, leakage
radiation emanates from the treatment enclosure and predominates the stray radiation dose
beyond about 30 cm. Monte Carlo simulations have been a useful research tool for modeling
stray dose [16–18], but these methods have not found use in clinical settings due to their
complexity and long computational times. The feasibility of analytical models to predict
stray dose from radiation therapy has been supported by several works [7, 19–25], but few
attempts have been made at developing models accurate for both in-ﬁeld and out-of-ﬁeld
doses. Jagetic and Newhauser reported on one such model that accurately predicts absorbed
dose from therapeutic, scatter, and leakage radiation [26]. This model was evaluated only at
6 MV photon-beam energy, only for Conformal Radiation Therapy (CRT), and only for one
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type of electron linear accelerator (Elekta, SL25, Stockholm). The study left open important
questions. Firstly, is this approach extensible to other treatment techniques, e.g., Intensity
Modulated Radiation Therapy (IMRT)? Secondly, is it adaptable to treatment units from
other manufacturers? Third, can it be done without proprietary data?
The objective of this study was to determine whether a physics-based analytical modeling
approach is applicable to a variety of treatment techniques and treatment units. More
speciﬁcally, we characterized the dosimetric accuracy that can be achieved without the
use of proprietary and machine-speciﬁc parameters to conﬁgure the model. In order to
accomplish this, we developed a new analytical model that can be conﬁgured with measured
dose proﬁles that are similar to those used for conﬁguring commercial treatment planning
systems. The model was tested using measured data from a variety of treatment machines
and techniques in the 6 to 25 MV interval of photon beam energy.
II. METHODS AND MATERIALS
A. Analytical Model
The analytical model consists of four terms: one to model the therapeutic radiation dose
and three to model sources of stray dose, or
DT = DP +DHS +DPS +DL , (1)
where DT is the total dose from all sources, DP is the primary dose term that models the
therapeutic dose, DHS is the ﬁrst stray dose term that models dose from head scattered radi-
ation, DPS is the second stray dose term that models dose from patient scattered radiation,
and DL is the third stray dose term that models leakage radiation.
Consequently, simplicity and ease of use were of prime importance to the model’s design.
In particular, we designed it for ease and simplicity of conﬁguration, e.g., by using non-
proprietary data that can be quickly measured in most clinics. The model proposed in this
work shares the major underlying physics and mathematical form as that of Jagetic and
Newhauser, but it was radically simpliﬁed here to streamline the conﬁguration process and
to eliminate the use of proprietary data. As will become readily apparent later, these two
features were of prime importance in conﬁguring the model for multiple treatment techniques
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and machines. Table I compares the two models and detailed descriptions of the terms from
this work follow below.
The primary absorbed dose, DP, for square and rectangular ﬁelds is given by
DP = AP × C(x, z)× C(y, z)× TFP,w(x, y, z, E) (2)
where AP governs the amplitude of the primary dose on the central axis, C(x, z) and C(y, z)
govern the width and lateral penumbrae of the beam in the x and y directions, x and y are
the lateral distances from central-axis in the plane of calculation for the in- and cross-plane
directions, and TFP,w(x, y, z, E) is the transmission factor of the primary portion of the
beam of nominal energy E at a point (x, y, z) in a phantom.
The C functions in (2) model the shape of the primary dose via the simple but realistic
approach of using cumulative normal distributions, as in
C(x, z) =
1
2piσ2(z)
×
{∫ x
−∞
exp
[−(x′ + x¯(z))2
2(σ2P(z))
]
dx′
}
×
{
1−
∫ x
−∞
exp
[−(x′ − x¯(z))2
2(σ2P(z))
]
dx′
}
. (3)
where σP(z) is the width parameter for the cumulative normal functions used to deﬁne the
penumbra, and x¯P(z) and y¯P(z) are the centroids of the cumulative normals projected to
depth z. These parameters are described in detail below.
The parameters σP(z), x¯(z), and y¯(z) are scaled with depth according to
σP(z) = σP,0 × FP(z) , (4)
x¯(z) = x¯P,0 × FP(z) , (5)
y¯(z) = y¯P,0 × FP(z) , (6)
where σP,0 is the width parameter in the isocentric plane, x¯P,0 and y¯P,0 are the lateral ﬁeld
edge locations in the isocentric plane. FP(z) is the scaling factor deﬁned as
FP(z) =
SSD+ diso + (z − diso)× αP
SSD+ diso
, (7)
where SSD is the source-to-surface distance, diso is the depth at isocenter, and αP is an
empirical correction factor to the rate at which σP(z), x¯P(z), and x¯P(z) change with depth.
The transmission factor in water at the calculation point is given by
TFP,w(x, y, z, E) = exp [−µP,eff × d(x, y, z)] , (8)
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TABLE I. Comparison of model terms for Jagetic and Newhauser [26] and this work.
Jagetic and Newhauser [26] This Work
Term Description Eqn. Description Eqn.
Uncollimated
Fluence, Φ
Modeled using electron
radiation yield, 3 Gaussian
source terms, and divergence.
(2.8) Not modeled. N/A
In-air Primary
Collimated Fluence,
ΦP
Uncollimated ﬂuence
multiplied by cumulative
normal.
(2.10) Implicitly modeled. (2)
Primary Dose in
Water, DP,w
In-air primary ﬂuence
multiplied by transmission
factor and mass-energy
absorption coeﬃcent.
(2.15)
Cumulative normal
multiplied by transmission
factor and primary scaling
factor.
(2)
Leakage Fluence, ΦL
Uncollimated ﬂuence
multiplied by complimentary
cumulative normal.
(2.17) Implicitly modeled. (18)
Leakage Dose in
Water, DL,w
Leakage ﬂuence multiplied by
transmission factors for
collimators and water and
mass-energy absorption
coeﬃcient.
(2.20)
Cumulative normal
multiplied by Gaussian
source term, water
transmission factors, and
energy dependent leakage
scaling factor.
(18)
Head-Scatter Dose
in Water, DHS,w
Gaussian multiplied by
empirical, ﬁeld-size
dependent, scaling factor and
water transmission factor.
(2.27)
Gaussian multiplied by
energy-dependent scaling
factor and water transmission
factor.
(11)
Patient-Scatter Dose
in Water, DPS,w
Dual Gaussians multiplied by
empirical, ﬁeld-size
dependent scaling factors and
water transmission factor.
(2.28)
Gaussian multiplied by
energy-dependent scaling
factor and water transmission
factor.
(14)
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where the path length through water to point (x, y, z) is
d(x, y, z) =
√
(SSD+ z)2 + x2 + y2 ×
(
z
SSD+ z
)
. (9)
The eﬀective linear photon attenuation coeﬃcient is
µP,eff(E) = (mµ,P × E + bµ,P)× µ|w,E¯ , (10)
where µP,eff(E) is the eﬀective linear attenuation coeﬃcient in water for the primary portion
of a beam of nominal energy E, and µ|w,E¯ is the linear attenuation coeﬃcient in water for
photons of energy E¯, where E¯ is the average energy of the photon beam approximated as one
third the value of the nominal energy following Jagetic and Newhauser [26]. The parameters
bµ,P and mµ,P are the 0th and 1st order coeﬃcients, respectively, of an empirical correction
factor to the eﬀective linear attenuation coeﬃcient that is parameterized with energy. This
factor is needed because µ|w,E¯ will not equal the true energy weighted mean of the linear
attenuation coeﬃcient, µ(E), across the full energy spectrum of the beam. The values of
the parameters bµ,P and mµ,P are determined along with the other ﬁtting parameters via
the model training procedure described in Section IIC. The values of µ|w,E¯ for the energies
considered in this study were found from the National Institute of Standards and Technology
(NIST) XCOM photon cross sections database [27].
The stray dose is the sum of three terms. The head scatter dose term is the narrowest
laterally and is given by
DHS(x, y, z, E) =
AHS(E)
σHS(z)
√
2pi
exp
[−(x2 + y2)
2σ2HS(z)
]
× TFHS,w(x, y, z, E) ,
(11)
where AHS(E) is the energy dependent scaling factor given by
AHS(E) = βHS × E + γHS , (12)
βHS and γHS are the 1st and 0th order coeﬃcients, respectively, that parameterize the factor
with photon beam energy. The depth dependent width parameter, σHS(z), is given by
σHS(z) = σHS,0 × FHS(z) , (13)
where σHS,0, is the head scatter width parameter in the isocentric plane, FHS(z) is deﬁned
similarly to (7) with empirical adjustment factor αHS , and TFHS,w(x, y, z, E) is the trans-
mission factor for head scattered radiation deﬁned similarly to (8).
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The patient scatter dose term is similarly given by
DPS(x, y, z, E) =
APS(E)
σPS(z)
√
2pi
exp
[−(x2 + y2)
2σ2PS(z)
]
× TFPS,w(x, y, E) ,
(14)
where APS(E) is the energy dependent scaling factor
APS(E) = βPS × E + γPS , (15)
βPS and γPS are the 1st and 0th order coeﬃcients, respectively, that parameterize the scaling
factor with photon beam energy, and σPS(z) is a depth dependent width parameter that
scales with depth according to
σPS(z) = σPS,0 × FHS(z) , (16)
where σPS,0 is the head scatter width parameter in the isocentric plane and FPS(z) is deﬁned
similarly to (7) with empirical adjustment factor αPS. The transmission factor for radiation
from patient scatter in a water phantom is given by
TFPS,w(x, y, E) = exp
(
−µPS,eff(E)×
√
x2 + y2
)
. (17)
The functional form of the leakage dose term is illustrated in Figure 1 and is deﬁned as
DL(x, y, z, E) =
AL(E)
σL(z)
√
2pi
exp
[−(x2 + y2)
2σ2L(z)
]
× TFL,w(x, y, z, E)× PC(r, z, E)
× [1− C(x, z)× C(y, z)] ,
(18)
where AL(E) is an energy dependent scaling factor
AL(E) = (βL × E + γL)Fφ , (19)
and Fφ accounts for increased leakage present in treatments with large amount of photon
ﬂuence modulation. The depth-dependent width parameter from (18) is
σL(z) = σL,0 × FL(z) , (20)
where FL(z) is deﬁned similarly to (7) with a corresponding empirical adjustment factor αL.
The factor [1− C(x, z)× C(y, z)] suppresses the leakage term inside the treatment ﬁeld, and
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PC(r, z, E) models attenuation in the primary collimator. This primary collimator function
is given by
PC(r, z, E) = 1− APC(E)×
∫ r
−∞
exp
[−(r′ + r¯(z))2
2σ2PC
]
dr′ , (21)
where r =
√
x2 + y2, APC(E) is the energy dependent scaling factor
APC(E) = βPC × E + γPC , (22)
σPC(z) is the width parameter of primary collimator penumbra given by
σPC(z) = σPC,0 × FL(z) , (23)
and r¯(z) is the lateral location of the primary collimator projected to depth z as in
r¯(z) = r¯0 × FL(z) . (24)
100
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FIG. 1. Functional form of the leakage dose, DL, versus oﬀ-axis distance, x. In the in-ﬁeld region,
the leakage dose is deﬁned to be zero. In the intermediate region, leakage is attenuated by the
secondary collimator. Far out of ﬁeld, there is additional attenuation from the primary collimator.
B. Measurements
There are three distinct sets of measured dosimetric data considered in this manuscript
summarized in Table II. The ﬁrst set was obtained in this study under the auspices of the
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European Radiation Dosimetry (EURADOS) Working Group 9 (WG9), a multinational col-
laboration of institutions and researchers dedicated to research and development in the ﬁeld
of radiation dosimetry in medicine [1]. These experiments were speciﬁcally designed to yield
dosimetric data that was needed to understand and model the physics of stray radiation
exposure. The measurement methods and a limited number of preliminary results were pre-
viously reported by Bordy et al [28] The EURADOS data set consists of measurements made
with multiple types thermoluminescent dosimeters (TLDs), radiophotoluminescent dosime-
ters (RPLs), and optically stimulated luminescent dosimeters (OSLDs) of doses delivered by
a Saturne 43 linac (GE Medical Systems, USA). The calibration procedure for the various
types of dosimeters is described by Knežević et al [29]. Doses were measured at various
locations inside a 30 x 30 x 60 cm3 water phantom. This data set includes dose proﬁles at
10, 15, 20, and 25 cm depths in water with a source-to-surface distance (SSD) of 90 cm,
a ﬁeld size of 10 x 10 cm2, and beam energies of 6, 12, and 20 MV. The irradiations each
delivered a reference dose of 2 Gy to the isocenter located at 10 cm depth. The measure-
ments from this data set are being prepared for distribution in the form of electronic ﬁles
containing complete tables of all numerical data and will be available for download from the
EURADOS website (http://www.eurados.org).
TABLE II. Manufacturers, machines, techniques, nominal photon energies, and measurement phan-
toms considered in this study.
Data Set MFR. Model Technique Beam Energy (MV) Phantom
EURADOS GE Saturne 43 CRT 6,12, 20 Water Box
KGU Elekta SL25 CRT 6, 18, 25 Water Box
(Halg et al.)
Varian Clinac 21 iX CRT, IMRT 6 Anthropomorphic
Elekta Synergy IMRT 6 Anthropomorphic
Siemens
Oncor Avant-Garde IMRT
6 Anthropomorphic
Mevatron Primus Wedge
Accuray
CyberKnife Stereotactic
6 Anthropomorphic
TomoTherapy Hi-Art 2 IMRT
The second data set used in this work comprises measurements performed at the Klinikum
Goethe Universität (KGU) in Frankfurt, Germany. The KGU data set measurements were
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made with a diamond detector model (60003 PTW, Freiburg) of doses delivered by an SL25
linac (Elekta, Stockholm) for various ﬁeld sizes, depths, and beam energies. For this work,
we consider 10 x 10 cm2 ﬁelds at depths of 1.5 and 3.5 cm in water and 100 cm SSD for beam
energies of 6, 18, and 25 MV. These measurements were previously published in Kaderka et
al [30].
The third data set used in this work comprises doses measured in an anthropomorphic
phantom (Alderson-Rando, RSD Radiology Support Devices, Long Beach, CA) for a variety
of widely used treatment machines and treatment techniques. These measurements were
previously published in Halg et al [31]. Prostate treatment plans were created for nine
treatment techniques from four manufacturers, including Accuray (Sunnyvale, CA, USA),
Elekta (Stockholm, Sweden), Varian Medical Systems (Palo Alto, CA, USA), and Siemens
(Berlin, Germany). All beams in this data set had a nominal energy of 6 MV. The dose
measurements were performed using TLDs placed inside the anthropomorphic phantom.
The dose along the medial patient axis was determined using 34 TLDs spaced at 2.5 cm
intervals from the target (in prostate) to the head.
C. Model Training
In this work, the analytical model was trained separately using the EURADOS and KGU
data sets. Training was accomplished by simultaneously ﬁtting the parameters listed in
Table V to measured dose values at all locations and at all beam energies. We used a
gradient search algorithm to vary the free parameters and minimize the sum of the local
relative diﬀerences, ∆DTotal, between the predicted and measured values. The sum of total
relative diﬀerences was deﬁned according to
∆DTotal =
n∑
i=1
∆Di =
n∑
i=1
[ |Dmodeli −Dmeasuredi |
(Dmodeli +D
measured
i ) /2
]
, (25)
where n is the number of data points. In order to characterize the goodness of ﬁt, we
calculated
∆D = ∆DTotal/n , (26)
where ∆D is the average local relative diﬀerence, and
∆Dmax = max ({∆D1, ...,∆Dn}) , (27)
where ∆Dmax is the maximum of the local relative diﬀerences.
This article is protected by copyright. All rights reserved. 
A
cc
ep
te
d 
A
rt
ic
le
D. Model Validation
The model, as conﬁgured and trained on both the KGU and EURADOS data sets, was
validated by comparison with independent data, namely, the measured dose proﬁles in an
anthropomorphic phantom for several treatment machines and techniques. Variations in
depth due to the irregular surface contour of the phantom were modeled implicitly since it
has been demonstrated that these variations are modest [24]. We compared the model as
trained on two independent training data sets in order to test the sensitivity of the agreement
to the choice of training data.
The quality assurance technique known as gamma analysis, ﬁrst described by Low et al
[32], characterizes the agreement between measured and calculated dose distributions on a
point by point basis by combining dose diﬀerence and distance to agreement criteria. In most
radiotherapy clinics, the dose diﬀerence criterion is selected at 3% of the maximum dose,
and the distance to agreement criterion at 3 mm. These values are commonly known as the
Van Dyk criteria [33]. However, this choice is not suitable for application far outside of the
treatment ﬁeld since dose in this region is well under 3% of the maximum dose, rendering
the test insensitive to important dose errors in the out-of-ﬁeld region. To overcome this
limitation, we extended the gamma index analysis method that is extended in order to
provide suﬃcient sensitivity and dynamic range to characterize dosimetric agreement in
both the in-ﬁeld and out-of-ﬁeld regions.
The gamma indices at all positions in therapeutic and out-of-ﬁeld dose regions were
calculated according to
Γ(xm, xc) =


√
r2(xm,xc)
∆d2
T
+
δ2
R
(xm,xc)
∆D2
R
, xm in/near ﬁeld√
r2(xm,xc)
∆d2
OOF
+
δ2
A
(xm,xc)
∆D2
A
, xm out-of-ﬁeld
(28)
where xm and xc are the locations of measured and calculated dose values, respectively.
r(xm, xc) is the diﬀerence in position between measured and calculated dose values, ∆dT
and ∆dOOF are the distance to agreement criteria in the therapeutic and out-of-ﬁeld re-
gions, respectively, δR(xm, xc) represents the relative dose diﬀerence between measured and
calculated dose values, ∆DR is the relative dose diﬀerence criterion, δA(xm, xc) represents
the absolute dose diﬀerence between measured and calculated dose values, and ∆DA is the
absolute dose diﬀerence criterion. The therapeutic dose region was delineated from the
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out-of-ﬁeld dose region at the 1% relative dose level based on previously published ﬁnd-
ings [26, 34–36]. This allows for a signiﬁcantly more severe dosimetric test out-of-ﬁeld than
conventional methods. Gamma index analysis was performed separately comparing the an-
alytical model calculations on each of the two training data sets to the anthropomorphic
phantom data set for the Varian Clinac 21 iX CRT. Gamma index pass rates were selected
at 100%, 95%, 90%, and 67%. The corresponding gamma index criteria were iteratively
decreased until the analysis yielded the selected pass rate.
III. RESULTS
A. Model Training
Figure 2 shows the Elekta SL25 measured and analytical model calculated total absorbed
dose values for the three nominal beam energies (6, 18, and 25 MV) from the KGU data
set. This ﬁgure demonstrates excellent agreement between measurement and analytical
model calculations across the range of nominal beam energies considered. Figure 3 shows
the measured absorbed dose from the 6 MV beam at a depth 1.5 cm in water plotted with
the analytical model calculated absorbed dose. The individual analytical model dose terms
(i.e. DP, DHS, DPS, DL) are also plotted thus demonstrating how the combination of these
terms yields excellent agreement in both the in- and out-of-ﬁeld regions. Table III shows
the average and local relative diﬀerences for the model compared with the KGU dataset
including the 6 MV beam at a depth of 1.5 cm and the 18 and 25 MV beams each at a depth
of 3.5 cm. The average local relative diﬀerence, deﬁned in (26), was 9.9%. The maximum
local relative diﬀerence, deﬁned in (27), was 33%.
TABLE III. Average and maximum local relative diﬀerences for all nominal photon beam energies
E for the model calculations compared with the Klinikum Goethe Universität (KGU) data set.
E ∆D(%) ∆Dmax(%)
6 MV 7.1 23.9
18 MV 12.3 32.9
25 MV 8.1 33.0
All Energies 9.9 33.0
This article is protected by copyright. All rights reserved. 
A
cc
ep
te
d 
A
rt
ic
le
100
101
102
103
104
105
 0  50  100  150  200  250  300  350  400  450
In/Near Field Out-of-Field

✭
 
✁
✂

✭
✄
✁
 
 
 
✭
☎
✆
✝
✆
✁
 (mm)
25 MV – Measured
25 MV – Calculated
18 MV – Measured
18 MV – Calculated
6 MV – Measured
6 MV – Calculated
FIG. 2. Measured and calculated relative absorbed dose D(x)/D(0) versus oﬀ-axis position x for all
beam energies from the Klinikum Goethe Universität (KGU) data set. The abscissa corresponds to
the lateral distance from the central axis of the beam. The ordinate represents the relative absorbed
dose as a function of x. All proﬁles are at dmax (1.5 cm for 6 MV and 3.5 cm for 18 and 25 MV) and
were normalized to the value of dose at x = 0. For visual clarity, the proﬁles are oﬀset by factors
of 10.
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FIG. 3. Measured and calculated relative absorbed dose D(x)/D(0) versus oﬀ-axis position x from
the 6 MV beam at 1.5 cm depth in water from the Klinikum Goethe Universität (KGU) data set.
Figure 4 shows plots of Saturne 43 measured and analytical model calculated absorbed
dose for the 6, 12, and 20 MV nominal beam energies at depths in water of 10 and 25 cm from
the model as trained with the EURADOS data set. Very good agreement is seen between
the model and the training data, showcasing the ability of the model to accurately calculate
absorbed dose across a range of energies and depths. Figure 5 show the measured absorbed
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dose from the 6 MV beam at a depth 10 cm in water plotted with the analytical model
calculated absorbed dose and all individual dose components. Table IV lists the average
and maximum local relative diﬀerences for all energies and depths included in this data set.
The average diﬀerence for all locations and energies considered was 9.9% and the maximum
diﬀerence was 41%.
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FIG. 4. Measured and calculated relative absorbed dose D(x)/Diso versus oﬀ-axis position x for 6,
12, and 20 MV beams at 10 cm and 25 cm depths in water from the European Radiation Dosimetry
Group (EURADOS) data set. The abscissa corresponds to distance from the central axis of the
beam. The ordinate corresponds to the relative absorbed dose as a function of x. The proﬁles
were normalized to the value of dose at isocenter for the given beam energy. For visual clarity, the
proﬁles were oﬀset from one another by factors of 10.
The model parameter values resulting from ﬁtting the model to the KGU and EURADOS
data sets of measurements in water are listed in Table V. The relative diﬀerences between the
parameters as ﬁt on these data sets are also listed. The primary dose parameters resulting
from ﬁtting the model to each of the two data sets are similar with no parameter diﬀering
by more than 33.5%. However, there are considerable diﬀerences between the parameters
for the out-of-ﬁeld dose components, thus highlighting the ability of the model to adapt to
out-of-ﬁeld dose proﬁles of diﬀerent machines.
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FIG. 5. Measured and calculated relative absorbed dose D(x)/D(0) versus oﬀ-axis position x for
the 6 MV beam at 10 cm depth in water from European Radiation Dosimetry Group (EURADOS)
data set.
TABLE IV. Average and maximum local relative diﬀerences for all nominal photon beam energies
and depths for the model calculations compared with the European Radiation Dosimetry Group
(EURADOS) data set.
6 MV 12 MV 20 MV All Energies
Depth (cm) ∆D(%) ∆Dmax(%) ∆D(%) ∆Dmax(%) ∆D(%) ∆Dmax(%) ∆D(%) ∆Dmax(%)
10 10.2 26.9 10.3 25.2 11.8 30.7 10.8 30.7
15 11.8 31.2 9.5 27.9 10.6 34.6 10.6 34.6
20 9.8 41 7.4 20.3 9.1 31.7 8.7 41
25 8.6 30.3 8.8 26.5 10.8 27.4 9.4 30.3
All depths 10.1 41 9 27.9 10.6 34.6 9.9 41
B. Validation with anthropomorphic phantom measurements
Doses measured in an anthropomorphic phantom for all nine treatment machines con-
sidered are shown in Figure 6. Also shown on this plot are the calculated doses from the
analytical model as trained on both the KGU and EURADOS data sets from the previous
section. The gamma index criteria required to achieve the selected passing rates are listed
in Table VI.
The large diﬀerences in leakage radiation seen in the measured proﬁles in Figure 6 are due
to diﬀerences in the ﬂuence modulation used for the diﬀerent techniques, as well as variations
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TABLE V. Model parameters for model as trained on Klinikum Goethe Universität (KGU) and
European Radiation Dosimetry Group (EURADOS) data sets and the relative diﬀerences between
the results for each.
Term Description Symbol KGU EURADOS Rel. Diﬀ.
Primary
Dose coeﬃcient AP (mGy/Gy) 982 1326 29.9%
Field edge x¯P,0 (cm) 5.0 4.9 1.4%
Penumbra σP,0 (cm) 0.33 0.33 1.6%
Projection correction factor αP (—) 1.1 0.78 33.5%
Attenuation 0th order coeﬃcient bµ,P (—) 0.7 0.8 13.7%
Attneuation 1st order coeﬃcient mµ,P (MeV-1) 5.2×10-2 5.7×10-2 8.5%
Head
Scatter
Dose 0th order coeﬃcient βHS (mGy/Gy) 5592 14619 89.3%
Dose 1st order coeﬃcient γHS (mGy/Gy/MeV) 722 263 93.3%
Width parameter αHS,0 (cm) 4.2 4.1 4.0%
Projection correction factor αHS (—) 0.88 0.79 10.8%
Attenuation 0th order coeﬃcient bµ,HS (—) -0.2 -0.3 34.3%
Attneuation 1st order coeﬃcient mµ,HS (MeV-1) 3.5×10-2 5.0×10-2 35.6%
Patient
Scatter
Dose 0th order coeﬃcient βPS (mGy/Gy) 8586 11666 30.4%
Dose 1st order coeﬃcient γPS (mGy/Gy/MeV) -145 -342 80.9%
Width parameter αPS,0 (cm) 15.0 12.0 21.9%
Projection correction factor αPS (—) 0.60 0.58 3.6%
Attenuation 0th order coeﬃcient bµ,PS (—) 0.98 0.58 51.0%
Attneuation 1st order coeﬃcient mµ,PS (MeV-1) -1.8×10-2 -1.5×10-2 13.7%
Leakage
Dose 0th order coeﬃcient βL (mGy/Gy) 10201 16967 49.8%
Dose 1st order coeﬃcient γL (mGy/Gy/MeV) -100 -613 143.9%
Width parameter αL,0 (cm) 340 239 34.8%
Projection correction factor αL (—) 0.80 0.80 0.7%
Attenuation 0th order coeﬃcient bµ,L (—) 2.02 1.20 51.1%
Attneuation 1st order coeﬃcient mµ,L (MeV-1) -4.7×10-2 -5.0×10-2 6.6%
PC 0th order coeﬃcient βPC (—) 0.44 0.33 29.3%
PC 1st order coeﬃcient γPC (MeV-1) 4.0×10-3 3.5×10-3 11.4%
PC location x¯PC (cm) 25.0 24.0 4.3%
PC penumbra σPC,0 (cm) 5.0×10-3 5.0×10-3 0.0%17
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FIG. 6. Relative absorbed dose D(x)/D(0) versus oﬀ-axis position x in anthropomorphic phantom
from irradiations by various treatment techniques and machines. Points represent measured doses.
Lines represent analytical model calculations from the model as trained on the Klinikum Goethe
Universität (KGU) and European Radiation Dosimetry Group (EURADOS) data sets, respectively.
in collimators and head shielding in various machines. For example, the increased leakage
from the CyberKnife unit was likely due to reduced head shielding in order to facilitate the
mounting of the linac on a robotic arm. On the other hand, the increased leakage from the
wedged ﬁeld technique was due to the greater beam-on time required to produce wedged
ﬁelds. Dose proﬁles from special techniques such as these should not be expected to closely
match the dose proﬁles of more typical treatment techniques, e.g., IMRT. By ﬁtting the
model parameters for each curve individually, it is possible to faithfully reproduce each of
the measured dose proﬁles in a descriptive capacity (not shown), but additional development
is necessary to extend the model to include explicit modeling of ﬂuence modulation for
predictive purposes.
IV. DISCUSSION
This work strongly suggests that there is potential for improving the completeness and
accuracy of dose distribution calculations in routine clinical applications. The model is not
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TABLE VI. Gamma index criteria for selected pass rates when comparing the model as trained on
the Klinikum Goethe Universität (KGU) and European Radiation Dosimetry Group (EURADOS)
data sets to the anthropomorphic phantom data set for the Varian Clinac 21 iX. The criteria
considered include relative dose diﬀerence, ∆DR; absolute dose diﬀerence, ∆DA; and distance to
agreement in the therapeutic and out-of-ﬁeld regions, ∆dt and ∆dOOF, respectively.
Therapeutic Out-of-Field
Training
Data Set
Pass
Rate
∆DR
(%)
∆dt
(mm)
∆DA(
mGy
Gy
) ∆dOOF
(mm)
KGU
100 8 18 3.5 0.5
95 6 14 3.1 0.5
90 4 10 2.2 0.5
67 3 7 0.3 0.5
EURADOS
100 15 20 4.5 0.5
95 11 16 3.9 0.5
90 8 12 2.5 0.5
67 6 8 0.6 0.5
intended to replace current methods of treatment planning, but could be used in conjunction
with current methods to provide a level of accuracy for the dose far outside the treatment
ﬁeld that is not available from currently available commercial treatment planning systems.
With further study, this model could be implemented for use in hand calculations of fetal dose
in the case of a pregnant radiation therapy patient or the dose to implants such pacemakers
that may be damaged by radiation. Additionally, the ability to calculate therapeutic and
stray radiation with a single model should be useful for studies in radiation epidemiology
or as an educational tool for demonstrating the shape and relative magnitudes of the dose
distributions from various treatment machines and techniques. Importantly, this may all be
possible with a single analytical model that users may implement with measured data that
is likely to already exist for their clinic.
The results of this study are coherent with previous works related to analytical models
of total dose from external beam radiation therapy. In particular, the results achieved in
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this work agree well with those of a more complex model previously reported by Jagetic and
Newhauser [26]. The model oﬀers simplicity, easy portability to various treatment machines
and techniques, and increased speed compared with the more detailed model of Jagetic and
Newhauser.
Major strengths of this study include the large number of treatment machines and tech-
niques considered. Whereas previous works have been limited to single treatment techniques,
this work considers nine techniques delivered with seven treatment machines from four man-
ufacturers. This is made possible by the simplicity of the reported model. Additionally, in
demonstrating the accuracies that are achievable with such a simple model, this work informs
about the tradeoﬀ between accuracy and complexity for analytical dose models.
Limitations of this work include the limited amount of measured data taken for each
treatment technique. Additionally, only the descriptive capabilities of the model have been
examined in this work, and the model’s ability to predict doses for treatments with diﬀerent
setup conditions has not been tested. This is not a serious limitation because a lookup
table approach could be used to apply this model to many diﬀerent setup conditions with
only a few measurements required. Another limitation of the model, in its current form,
is the lack of photoneutrons at beam energies greater than 10 MV. However, this is not
a serious limitation because most external beam photon treatments are delivered with 6
MV beams. This is especially true of IMRT. Additionally, for beam energies up to 18 MV,
the component of equivalent dose due to photoneutrons is a small fraction of that due to
leakage photons [30]. Also, the model can be extended to include photoneutrons in future
studies. Other future work should include testing the model for dosimetric accuracy under
diﬀerent treatment conditions, such as ﬁeld size. Additionally, implementing the model
into a treatment planning system would allow for further testing of the practicality of using
analytical models of stray dose in clinical settings. Our research group has recently performed
similar work by implementing an analytical model of neutron dose from passively-scattered
proton therapy into a research treatment planning system [37].
V. CONCLUSION
In this work we developed a new, broadly-applicable analytical model of the total dose
from external beam radiation therapy. The model provides very good accuracy, on average
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better than 10%, for both therapeutic and stray dose for a wide variety of treatment machines
and techniques when compared with measured data. Importantly, the model developed here
may be conﬁgured using non-proprietary conﬁguration parameters and dosimetric data that
is readily measurable in most clinics.
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